Alnylam Pharmaceuticals Inc to Discuss APOLLO-B Results at HFSA Scientific Meeting Transcript
Welcome, everyone. Glad to have you here at HFSA. This is Alnylam's first in-person investor event post pandemic. So we're really extra pleased to have you here as well. I'm Christine Regan Lindenboom, I am the Senior Vice President of Investor Relations and Corporate Communications at Alnylam. And we've got a great panel with us today. So we'll have Pushkal Garg, our Chief Medical Officer, give some opening remarks. Matt Mauer is joining us from Columbia University, and he will review the data that was presented earlier today. And then we'll go through some summary next steps. We'll then have Tolga Tanguler, our Chief Commercial Officer, join us for Q&A as well as John Vest, our Vice President of Clinical Research as well. Before we start, I wanted to share some forward-looking statements, please review those at your leisure.
And then we will take Q&A both from the room as well as from the webcast, if you're on the webcast and you have a question, feel free to type it in ask a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |